Clinical trials: Neoadjuvant Treatment
Breast Cancer
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women
The purpose of the study was to determine whether treatment with a PI3K inhibitor plus letrozole led to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in…
- Trial name
- NCT01923168
- Testing
- alpelisib, buparlisib
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 340 people
- Sponsor
- Novartis Pharmaceuticals
Bladder Cancer
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
In the treatment of localized/locally advanced urothelial cancer, there are several questions that have not yet been resolved, such as the limited benefit of cisplatin-based chemotherapy in the adjuvant or neoadjuvant context…
- Trial name
- DUTRENEO (NCT03472274)
- Testing
- Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy
- Where
- 11 sites in Spain
- Volunteers
- 101 people
- Sponsor
- Fundacion CRIS de Investigación para Vencer el Cáncer
Head and Neck Neoplasms
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
This is a randomized, active-controlled, open-label study of pembrolizumab given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in…
- Trial name
- NCT03765918
- Testing
- Pembrolizumab 200 mg, Radiotherapy 60 Gray, Radiotherapy 66 Gray
- Where
- 192 sites in United States, Argentina and 22 more
- Volunteers
- 714 people
- Sponsor
- Merck Sharp & Dohme LLC
Infant-Type Hemispheric Glioma
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
The purpose of this study is to test whether giving treatment before surgery helps babies who are newly diagnosed with Infant-Type Hemispheric Glioma (IHG) have safer and better surgery results.
- Trial name
- NCT07916389
- Testing
- Alectinib, Entrectinib, Surgery
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- St. Jude Children's Research Hospital
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Locally Advanced Cervical Cancer
Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
The goal of this clinical trial is to learn if Iparomlimab/Tuvonralimab combined with nab-paclitaxel and cisplatin as neoadjuvant treatment can treat locally advanced cervical cancer in adult female patients.
- Trial name
- NCT07876154
- Testing
- Iparomlimab/Tuvonralimab, nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Xijing Hospital
Lung Cancer
Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC
This study is a prospective, single-arm, single-center Phase II trial, aiming to investigate efficacy and safety of neoadjuvant chemotherapy sequentially combined with sintilimab in resectable EGFR-mutant stage II-IIIB…
- Trial name
- Peri-E (NCT06688656)
- Testing
- Pemetrexed 500 mg/m2, carboplatin, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Triple Negative Breast Cancer Patients
Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen
This is a single arm, single center, non-randomized, phase II trial of stage IIB/III TNBC. Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500…
- Trial name
- CAPneo (NCT03304756)
- Testing
- CAP
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Muscle Invasive Bladder Cancer (MIBC)
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder…
- Trial name
- HARBOR (NCT07296705)
- Testing
- Zanidatamab, Tislelizumab, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 25 people
- Sponsor
- Fujian Medical University Union Hospital
Colorectal Cancer
Neoadjuvant Electrochemotherapy for Colorectal Cancer - a Randomized Controlled Trial
This is a randomized controlled trial investigating efficacy of electrochemotherapy for early colorectal cancer
- Trial name
- NCT04816045
- Testing
- Electrochemotheraoy
- Volunteers
- 24 people
- Sponsor
- Zealand University Hospital
Prostate Cancer
Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy
There is now substantial evidence that B cells are recruited into prostate cancers by CXCL13 released by the tumor cells. B cells release lymphotoxin which drives malignant cell proliferation through the NFkB pathway.
- Trial name
- NCT01804712
- Testing
- rituximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Christopher Kane
Colorectal Cancer
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00814619
- Testing
- panitumumab, capecitabine, therapeutic conventional surgery
- Where
- 24 sites in Hungary, Switzerland
- Volunteers
- 68 people
- Sponsor
- Swiss Cancer Institute
Anemia
Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy
This is an open-label, single institution study evaluating the efficacy of intravenous iron sucrose monotherapy in patients with thoracic, breast, GU and GI malignancies undergoing neoadjuvant chemotherapy with the goal of…
- Trial name
- Iron-RANC (NCT05800600)
- Testing
- Venofer
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Fox Chase Cancer Center
Melanoma
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
This is a phase II study testing the safety and preliminary efficacy of triplet ICB in treatment naïve patients with clinical stage III or oligometastatic stage IV melanoma with resectable disease.
- Trial name
- NCT07511036
- Testing
- Cemiplimab, Lpilimumab, Fianlimab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Gastric Cancer
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
To evaluate the safety and effectiveness of laparoscopic gastrectomy (LG) following neoadjuvant immunochemotherapy (nICT)
- Trial name
- NCT06235164
- Testing
- immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab
- Where
- China
- Volunteers
- 585 people
- Sponsor
- Fujian Medical University
Breast Cancer
DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy
This study evaluates whether radiotherapy can safely be omitted in breast cancer patients with T1-2N0 tumors who achieve a pathologic complete response after neoadjuvant systemic therapy and breast-conserving surgery
- Trial name
- NCT05416164
- Testing
- Omission of radiotherapy
- Where
- Netherlands
- Volunteers
- 595 people
- Sponsor
- The Netherlands Cancer Institute
Rectal Cancer
Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy
The purpose of this study is evaluation of the safety and the efficacy of transanal local excision in patients with cT3 rectal cancer which was downstaged into ycT0-1 after neoadjuvant chemoradiotherapy.
- Trial name
- NCT02490709
- Testing
- Local excision
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- National Cancer Center, Korea
Ocular Melanoma
Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye
The purpose of this study is to explore whether the drug pegylated-interferon-alfa-2b (PEG-IFN) has any effect on a certain type of immune cell (called natural killer cells) in patients with eye melanoma.
- Trial name
- NCT00621439
- Testing
- Pegylated Interfon Alpha 2B
- Sponsor
- Emory University
Colorectal Cancer (CRC)
Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer
This is a prospective, open-label, randomized, parallel-group phase II trial evaluating the efficacy and safety of a low-dose radiotherapy sensitization strategy combined with a PD-1 antibody (pucotenlimab) and CAPEOX as…
- Trial name
- NCT07448142
- Testing
- Low-dose radiotherapy, Pucotenlimab, CAPEOX/XELOX
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Renal Pelvis and Ureter Urothelial Carcinoma
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
This phase Ib trial studies the side effects of infigratinib before surgery in treating patients with upper tract urothelial cancer.
- Trial name
- NCT04228042
- Testing
- Infigratinib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.